On April 1, 2025 Vivesto AB, an oncology-focused development company, reported that positive preclinical efficacy data was obtained in an animal model of hematological cancer (Press release, Vivesto, APR 1, 2025, View Source [SID1234651725]). The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe.

"This is a significant milestone for the Cantrixil program. Obtaining positive efficacy data in vivo is not only important from a regulatory perspective, but it is also imperative in the development path towards showing potential benefits of Cantrixil in hematological cancer also in patients. Importantly, the treatment was also well tolerated. With these new results we are increasingly confident that Cantrixil can make a significant impact to patients and as well as build shareholder value," said Erik Kinnman, CEO of Vivesto.

With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.